Serum Metabolomic Profiling Reveals Differences Between Systemic Sclerosis Patients with Polyneuropathy
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26157133 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Kristine Ivanova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Doctoral Studies, Rīga Stradinš University, LV-1050 Rīga, Latvia. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Metabolomics, Polyneuropathies, Metabolome. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: RSU internal and RSU with LASE external consolidation, European Union’s Horizon 2020 research and innovation programme.
Abstract (Originalsprache)
Metabolome studies have already been carried out in patients with systemic sclerosis (SSc). However, polyneuropathy (PNP) as a complication of SSc has been overlooked in these studies. To the best of our knowledge, this is the first study to examine metabolic changes in SSc patients with PNP. Patients with SSc (n = 62) and a healthy control group (HC) (n = 72) were recruited from two Latvian hospitals. Blood plasma samples were collected and analyzed using an LC-MS-based targeted metabolomics workflow. Our plasma sample cohort consisted of 62 patients with SSc, 42% of whom had PNP. Differences between SSc patients and the HC group with fold changes > 2 were observed for aspartic acid, glutamic acid, valine, and citrulline, all of which were reduced. In contrast to the SSc to HC discrimination, no metabolites had a high fold change; only minor changes were observed using FC > 1.3. We identified elevated concentrations of kynurenine, asparagine, and alanine. Changes in metabolite regulation in patients with SSc, compared to controls, are not identical to those observed in SSc patients with PNP, with elevated concentrations of kynurenine and alanine specific to the SSc subgroup. SSc patients with PNP should probably be considered a distinct population with important metabolomic features.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Doctoral Studies, Rīga Stradinš University, LV-1050 Rīga, Latvia.
- Institute of Oncology and Molecular Genetics, Rīga Stradinš University, LV-1050 Rīga, Latvia.
- Department of Rheumatology, Pauls Stradiņš Clinical University Hospital, LV-1002 Rīga, Latvia.
- Baltic Biomaterials Centre of Excellence, Headquarters at Riga Technical University, LV-1048 Rīga, Latvia.
- Institute of Biomaterials and Bioengineering, Faculty of Natural Sciences and Technology, Riga Technical University, LV-1048 Rīga, Latvia.
- Department of Biology and Microbiology, Rīga Stradinš University, LV-1050 Rīga, Latvia.
ORCID-Profile: Kristine Ivanova, Annija Vaska
Förderung
- RSU internal and RSU with LASE external consolidation
- European Union’s Horizon 2020 research and innovation programme
Zitieren
APA
Ivanova, K., Schiemer, T., Vaska, A., Kurjāne, N., Kenina, V., & Klavins, K. (2025). Serum Metabolomic Profiling Reveals Differences Between Systemic Sclerosis Patients with Polyneuropathy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157133
Vancouver
Ivanova K, Schiemer T, Vaska A, Kurjāne N, Kenina V, Klavins K. Serum Metabolomic Profiling Reveals Differences Between Systemic Sclerosis Patients with Polyneuropathy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157133
BibTeX
@article{Ivanova2025,
author = {Ivanova, Kristine and Schiemer, Theresa and Vaska, Annija and Kurjāne, Nataļja and Kenina, Viktorija and Klavins, Kristaps},
title = {Serum Metabolomic Profiling Reveals Differences Between Systemic Sclerosis Patients with Polyneuropathy},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26157133}
}
EUVIMED